EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials

Haibing Dai, Yonglin Zhu, Zuyi Chen, Renqing Yan, Jinsong Liu, Ziyun He, Lin Zhang, Feng Zhang, Shengkai Yan

Endokrynologia Polska · 26.06.2023 · 74 (3) · 234-242

DOI: 10.5603/ep.a2023.0036 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Endokrynologia Polska, online erschienen am 26.06.2023. Verfasst von Haibing Dai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China. 2832845671@qq.com. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Anticholesteremic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IIAnticholesteremic AgentsHumansAntibodies, MonoclonalLipoprotein(a)Randomized Controlled Trials as TopicAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

PCSK9 inhibitorsatherosclerotic cardiovascular diseasefamilial hypercholesterolaemialipoprotein (a)meta-analysisrandomized controlled trials

Substanzen

Antibodies, MonoclonalLipoprotein(a)Anticholesteremic AgentsevolocumabAntibodies, Monoclonal, Humanizedalirocumab

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China. 2832845671@qq.com.
  • College of Laboratory Medicine, Zunyi Medical University, Zunyi, China. 2832845671@qq.com.
  • Department of Laboratory Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
  • College of Laboratory Medicine, Zunyi Medical University, Zunyi, China.
  • School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Zitieren

APA

Dai, H., Zhu, Y., Chen, Z., Yan, R., Liu, J., He, Z., Zhang, L., Zhang, F., & Yan, S. (2023). Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials. Endokrynologia Polska, 74(3), 234-242. https://doi.org/10.5603/ep.a2023.0036

Vancouver

Dai H, Zhu Y, Chen Z, Yan R, Liu J, He Z, et al. Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials. Endokrynologia Polska. 2023;74(3):234-242. doi:10.5603/ep.a2023.0036

BibTeX
@article{Dai2023,
  author = {Dai, Haibing and Zhu, Yonglin and Chen, Zuyi and Yan, Renqing and Liu, Jinsong and He, Ziyun and Zhang, Lin and Zhang, Feng and Yan, Shengkai},
  title = {Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials},
  journal = {Endokrynologia Polska},
  year = {2023},
  volume = {74},
  number = {3},
  pages = {234--242},
  doi = {10.5603/ep.a2023.0036}
}
Kostenlos starten →